

## REFERENCES

- Baldino, F., Jr., Chesselet, M.F. and Lewis, M.E. (1989). High-resolution in situ hybridization histochemistry. *Methods Enzymol*, **168**, 761-77.
- Bar-Sagi, D. (2001). A Ras by any other name. *Mol Cell Biol*, **21**, 1441-3.
- Bell, D.A. and DeMarini, D.M. (1991). Excessive cycling converts PCR products to random-length higher molecular weight fragments. *Nucleic Acids Res*, **19**, 5079.
- Berek, J.S. (2002). Ovarian cancer. In *Novak's gynecology* pp. 1245-1307. Williams and Wilkins.
- Bos, J.L. (1989). ras oncogenes in human cancer: a review. *Cancer Res*, **49**, 4682-9.
- Caduff, R.F., Svoboda-Newman, S.M., Ferguson, A.W., Johnston, C.M. and Frank, T.S. (1999). Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. *Am J Surg Pathol*, **23**, 323-8.
- Cuatrecasas, M., Erill, N., Musulen, E., Costa, I., Matias-Guiu, X. and Prat, J. (1998). K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. *Cancer*, **82**, 1088-95.
- Cuatrecasas, M., Villanueva, A., Matias-Guiu, X. and Prat, J. (1997). K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. *Cancer*, **79**, 1581-6.
- Eckert, K.A. and Kunkel, T.A. (1990). High fidelity DNA synthesis by the *Thermus aquaticus* DNA polymerase. *Nucleic Acids Res*, **18**, 3739-44.
- Ellis, C.A. and Clark, G. (2000). The importance of being K-Ras. *Cell Signal*, **12**, 425-34.
- Ellsworth, D.L., Rittenhouse, K.D. and Honeycutt, R.L. (1993). Artifacts in randomly amplified polymorphic DNA banding patterns. *Biotechniques*, **14**, 214-7.
- Enomoto, T., Inoue, M., Perantoni, A.O., Buzard, G.S., Miki, H., Tanizawa, O. and Rice, J.M. (1991a). K-ras activation in premalignant and malignant epithelial lesions of the human uterus. *Cancer Res*, **51**, 5308-14.

- Enomoto, T., Inoue, M., Perantoni, A.O., Terakawa, N., Tanizawa, O. and Rice, J.M. (1990). K-ras activation in neoplasms of the human female reproductive tract. *Cancer Res*, **50**, 6139-45.
- Enomoto, T., Weghorst, C.M., Inoue, M., Tanizawa, O. and Rice, J.M. (1991b). K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. *Am J Pathol*, **139**, 777-85.
- Fujita, M., Enomoto, T. and Murata, Y. (2003). Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. *Mol Cell Endocrinol*, **202**, 97-9.
- Garrett, A.P., Lee, K.R., Colitti, C.R., Muto, M.G., Berkowitz, R.S. and Mok, S.C. (2001). k-ras mutation may be an early event in mucinous ovarian tumorigenesis. *Int J Gynecol Pathol*, **20**, 244-51.
- Gemignani, M.L., Schlaerth, A.C., Bogomolny, F., Barakat, R.R., Lin, O., Soslow, R., Venkatraman, E. and Boyd, J. (2003). Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. *Gynecol Oncol*, **90**, 378-81.
- Haas, B., Hinz, K.H. and Glunder, G. (1999). Biotin-streptavidin enzyme-linked immunosorbent assay for the detection of antibodies to *Campylobacter jejuni* and *C. coli* in chickens. *Zentralbl Veterinarmed B*, **46**, 163-71.
- Hanahan, D. and Weinberg, R.A. (2000). The hallmarks of cancer. *Cell*, **100**, 57-70.
- Hatzaki, A., Razi, E., Anagnostopoulou, K., Iliadis, K., Kodaxis, A., Papaioannou, D., Labropoulos, S., Vasilaki, M., Kosmidis, P., Saetta, A., Mihalatos, M. and Nasioulas, G. (2001). A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients. *Mol Cell Probes*, **15**, 243-7.
- Hogdall, E.V., Hogdall, C.K., Blaakaer, J., Christensen, L., Bock, J.E., Vuust, J., Glud, E. and Kjaer, S.K. (2003). K-ras alterations in Danish ovarian tumour patients. From the Danish "Malova" Ovarian Cancer study. *Gynecol Oncol*, **89**, 31-6.
- Ichikawa, Y., Nishida, M., Suzuki, H., Yoshida, S., Tsunoda, H., Kubo, T., Uchida, K. and Miwa, M. (1994). Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. *Cancer Res*, **54**, 33-5.

- Ishioka, S., Sagae, S., Terasawa, K., Sugimura, M., Nishioka, Y., Tsukada, K. and Kudo, R. (2003). Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system. *Gynecol Oncol*, **89**, 447-52.
- Jenkins, G.J., Williams, G.L., Beynon, J., Ye, Z., Baxter, J.N. and Parry, J.M. (2002). Restriction enzymes in the analysis of genetic alterations responsible for cancer progression. *Br J Surg*, **89**, 8-20.
- Kitago, M., Ueda, M., Aiura, K., Suzuki, K., Hoshimoto, S., Takahashi, S., Mukai, M. and Kitajima, M. (2004). Comparison of K-ras point mutation distributions in intraductal papillary-mucinous tumors and ductal adenocarcinoma of the pancreas. *Int J Cancer*, **110**, 177-82.
- Li, D., Firozi, P.F., Zhang, W., Shen, J., DiGiovanni, J., Lau, S., Evans, D., Friess, H., Hassan, M. and Abbruzzese, J.L. (2002). DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. *Mutat Res*, **513**, 37-48.
- Longley, M.J., Bennett, S.E. and Mosbaugh, D.W. (1990). Characterization of the 5' to 3' exonuclease associated with *Thermus aquaticus* DNA polymerase. *Nucleic Acids Res*, **18**, 7317-22.
- Maeshima, A., Sakamoto, M. and Hirohashi, S. (2002). Mixed mucinous-type and non-mucinous-type adenocarcinoma of the lung: immunohistochemical examination and K-ras gene mutation. *Virchows Arch*, **440**, 598-603.
- Mandai, M., Konishi, I., Komatsu, T., Mori, T., Arao, S., Nomura, H., Kanda, Y., Hiai, H. and Fukumoto, M. (1995). Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression. *Br J Cancer*, **72**, 691-5.
- Mandai, M., Konishi, I., Kuroda, H., Komatsu, T., Yamamoto, S., Nanbu, K., Matsushita, K., Fukumoto, M., Yamabe, H. and Mori, T. (1998). Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. *Hum Pathol*, **29**, 34-40.
- Matias-Guiu, X. and Prat, J. (1998). Molecular pathology of ovarian carcinomas. *Virchows Arch*, **433**, 103-11.

- Mayr, D. and Diebold, J. (2003). Chromosomal changes in ovarian cancer. *Current Diagnostic Pathology*, **5**, 328-332.
- Mok, S.C., Bell, D.A., Knapp, R.C., Fishbaugh, P.M., Welch, W.R., Muto, M.G., Berkowitz, R.S. and Tsao, S.W. (1993). Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. *Cancer Res*, **53**, 1489-92.
- Morita, K., Ono, Y., Fukui, H., Tomita, S., Ueda, Y., Terano, A. and Fujimori, T. (2000). Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors. *Pathol Int*, **50**, 219-23.
- Ozols, R.F. (1991). Ovarian cancer: new clinical approaches. *Cancer Treat Rev*, **18 Suppl A**, 77-83.
- Pieretti, M., Cavalieri, C., Conway, P.S., Gallion, H.H., Powell, D.E. and Turker, M.S. (1995). Genetic alterations distinguish different types of ovarian tumors. *Int J Cancer*, **64**, 434-40.
- Rychlik, W., Spencer, W.J. and Rhoads, R.E. (1990). Optimization of the annealing temperature for DNA amplification in vitro. *Nucleic Acids Res*, **18**, 6409-12.
- Saiki, R.K., Scharf, S., Faloona, F., Mullis, K.B., Horn, G.T., Erlich, H.A. and Arnheim, N. (1985). Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. *Science*, **230**, 1350-4.
- Scambia, G., Masciullo, V., Benedetti Panici, P., Marone, M., Ferrandina, G., Todaro, N., Bellacosa, A., Jain, S.K., Neri, G., Piffanelli, A. and Mancuso, S. (1997). Prognostic significance of ras/p21 alterations in human ovarian cancer. *Br J Cancer*, **75**, 1547-53.
- Speed, T.P., McPeck, M.S. and Evans, S.N. (1992). Robustness of the no-interference model for ordering genetic markers. *Proc Natl Acad Sci U S A*, **89**, 3103-6.
- Teneriello, M.G., Ebina, M., Linnoila, R.I., Henry, M., Nash, J.D., Park, R.C. and Birrer, M.J. (1993). p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. *Cancer Res*, **53**, 3103-8.
- Williams, J.F. (1989). Optimization strategies for the polymerase chain reaction. *Biotechniques*, **7**, 762-9.